Theriva Biologics Files 8-K on Financial Obligation

TL;DR

Theriva Biologics just took on a new financial obligation, filing an 8-K today.

AI Summary

On September 16, 2024, Theriva Biologics, Inc. filed an 8-K report detailing a direct financial obligation. The company, formerly known as Synthetic Biologics, Inc., is incorporated in Nevada and operates in the Pharmaceutical Preparations sector. This filing indicates a new financial commitment or arrangement for the company.

Why It Matters

This filing signals a new financial commitment for Theriva Biologics, which could impact its financial health and future strategic decisions.

Risk Assessment

Risk Level: medium — Filings related to direct financial obligations can introduce new risks or opportunities that may affect the company's stock price.

Key Players & Entities

• Theriva Biologics, Inc. (company) — Registrant
• Synthetic Biologics, Inc. (company) — Former company name
• September 16, 2024 (date) — Date of earliest event reported
• Nevada (jurisdiction) — State of incorporation
• 2834 (industry_code) — Standard Industrial Classification (Pharmaceutical Preparations)

FAQ

Key Financial Figures

• $0.001 — h registered Common stock, par value $0.001 per share TOVX NYSE American Indica

Filing Documents

• tm2424064d1_8k.htm (8-K) — 29KB
• tm2424064d1_ex99-1.htm (EX-99.1) — 13KB
• tm2424064d1_ex99-1img001.jpg (GRAPHIC) — 4KB
• 0001104659-24-100010.txt ( ) — 225KB
• syn-20240916.xsd (EX-101.SCH) — 3KB
• syn-20240916_lab.xml (EX-101.LAB) — 33KB
• syn-20240916_pre.xml (EX-101.PRE) — 22KB
• tm2424064d1_8k_htm.xml (XML) — 4KB

03 Creation of a Direct Financial Obligation or an Obligation

Item 2.03 Creation of a Direct Financial Obligation or an Obligation Under an Off-balance Sheet Arrangement of a Registrant. The information set forth under Item 8.01 below of this Current Report on Form 8-K is incorporated by reference in this Item 2.03.

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On September 16, 2024, Theriva Biologics, Inc. (the "Company") issued a press release announcing that its THERICEL project has been awarded funding of 2.28 million from the National Knowledge Transfer Program of the Spanish government's Ministry of Science, Innovation & Universities to support a collaboration between the Company and the Universitat Autnoma de Barcelona ("UAB") to advance the Company's suspension cell platform for the clinical manufacture of adenovirus- and adeno-associated virus ("AAV") therapies. Under the award, the Company will receive an unsecured loan of 1.33 million as a lump sum payment in Q4 2024 which shall bear interest at a rate of 4.015% and be repaid over 7 years commencing three years from the date of award and UAB will receive a grant of 0.95 million dedicated to the THERICEL project and paid in annual installments over the next 3 years. The information in this Item 7.01 and in the press release furnished as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended and shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. The press release furnished as Exhibit 99.1 to this Current Report on Form 8-K includes "safe harbor" language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are "forward-looking" rather than historical.

01. Other Events

Item 8.01. Other Events. On September 16, 2024, the Company issued a press release announcing that its THERICEL project has been awarded funding of 2.28 million from the National Knowledge Transfer Program of the Spanish government's Ministry of Science, Innovation & Universities to support a collaboration with UAB to advance the Company's suspension cell platform for the clinical manufacture of AAV therapies. Under the award, the Company will receive an unsecured loan of 1.33 million as a lump sum payment in Q4 2024 which shall bear interest at a rate of 4.015% and be repaid over 7 years commencing three years from the date of award and UAB will receive a grant of 0.95 million dedicated to the THERICEL project and paid in annual installments over the next 3 years. The Company intends to execute the loan documents upon receipt thereof.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release issued by Theriva Biologics, Inc., dated September 16, 2024 104 Cover Page Interactive Data File (embedded within the XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 16, 2024 THERIVA BIOLOGICS, INC. By: /s/ Steven A. Shallcross Name: Steven A. Shallcross Title: Chief Executive Officer and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR